source
- Amgen launches late-stage obesity trial in patients who switch from rival drugsAmgen is launching three new late-stage trials for its long-acting obesity shot MariTide, including one designed to test the drug in patients switching away from Eli Lilly and Novo Nordisk's blockb…Endpoints · 2mo ago↗ source
- Q&A: Seaport CEO and CSO on learning from Karuna and the future of CNS researchSeaport Therapeutics began trading as a public company on Friday after executives rang the Nasdaq’s opening bell. Shares rose {$SPTX} more than 20%. With a team largely made up of Karuna Therapeuti…Endpoints · 2mo ago↗ source
- Summit’s ‘self-inflicted’ stumble; Esperion’s take-private dealSummit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast c…